world-biomarkers-pharma-biotech-2017-posters

12 / 61

Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 68
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Mebendazole in giardiasis : Systematic review and meta-analysis
Pedro Almirall1, Angel A Escobedo2, Eduardo González-Fraile3 and Javier Ballesteros 4
1Ministry of Public Healthof Cuba, Cuba
2Hospital Pediátrico Borrás-Marfan, Cuba
3Institute of Psychiatric Research, Spain
4University of the Basque Country, Spain
Introduction: At present, 5-nitroimidazole compounds are the pharmacological cornerstone for people with Giardia infections.
However, treatment failures are increasingly reported. Mebendazole (MBZ), a benzimidazole compound, has received attention
in treating patients with giardiasis since beneficial effects have been demonstrated in vitro and in vivo.
Aim: The aim of this study was to assess in a systematic review and meta-analysis of randomized controlled trials (RCTs) the
efficacy of MBZ compared to other antigiardial agents in children.
Methods: RCTs of MBZ for the treatment of Giardia infections published in PubMed and EBSCO host were searched.
Application of inclusion and exclusion criteria, data extraction, and assessment of methodological quality were independently
performed in duplicate. The endpoint was the parasitological response to therapy.
Results: Seven RCTs were found in the systematic review (639 patients) and were included in the meta-analysis. There is not
clinical difference in the parasitological cure between MBZ and metronidazole (MTZ). The relative risk (RR) is 0.88 (95% CI
0.70-1.10), with a moderate heterogeneity (I2=66%). The prediction interval expected to cover the results of a new trial is wide
enough (0.35-2.21) to support both a parasitological relevant difference favoring MBZ and a parasitological relevant difference
favoring MTZ.
Conclusions: This study synthesized available evidence on (and documented) the efficacy of MBZ in treating Giardia infection
in children. There is no difference in efficacy between MBZ and MTZ regarding parasitological cure. Hence, the decision to
support any of the competing treatments should be based nit in efficacy but, in other characteristics such as tolerance with the
treatment or associated costs. Although our results suggest that MBZ may be an effective treatment option for children with
Giardia infection, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based
on a limited number of heterogeneous RCTs.
Recent Publications:
1. Escobedo A A, Almirall P, Cimerman S and Rodríguez-Morales A J (2016) Sequelae of giardiasis: an emerging public-
health concern. International Journal of Infectious Diseases. 49: 202-203.
2. Escobedo A A, Almirall P, Robertson L J, Mørch K, Franco R M, Hanevik K and Cimerman S (2010) Giardiasis: the
ever-present threat of a neglected disease. Infectious Disorders - Drug Targets. 10: 329-348.
3. Escobedo A A, Cimerman S and Almirall P (2011) An old drug against giardiasis: mebendazole as a treatment option.
Infectious Disorders - Drug Targets. 11: 94-95.
4. Escobedo A A, Lalle M, Hrastnik N I, Rodríguez-Morales A J, Castro-Sánchez E, Cimerman S, Almirall P and Jones J
(2016) Combination therapy in the management of giardiasis: what laboratory and clinical studies tell us so far. Acta
Tropica. 162: 196-205.
5. Escobedo A A, Ballesteros J, González-Fraile E and Almirall P (2016) A meta-analysis of the efficacy of albendazole
compared with tinidazole as treatments for Giardia infections in children. Acta Tropica. 153 (2): 120–127
Biography
Pedro Almirall has his expertise giardiasis pharmacotherapy and public health. He has been working for years as a Clinical Epidemiologist and has experience
in research, evaluation, and teaching, both in Cuban hospitals and education institutions. He has published his research in international scientific journals and
currently, he is pursuing his PhD.
Pedro Almirall et al., J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110